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Rehabilitation of Neuromyelitis Optica (Devic’s Syndrome):  3 Case Reports  1 
Abstract 2 
We describe the inpatient clinical rehabilitation course of three patients with 3 
neuromyelitis optica (NMO; Devic’s Syndrome). These patients had varying functional 4 
deficits.  Each patient improved in several functional independence measures (FIM 5 
domains), but had minimal to no progress in other domains after acute rehabilitation stays 6 
between 1 to 1.5 months.  NMO is a severe central nervous system demyelinating 7 
syndrome distinct from MS, characterized by optic neuritis, myelitis, and at least two of 8 
three criteria: longitudinally extensive cord lesion, MRI nondiagnostic for multiple 9 
sclerosis, or NMO-IgG seropositivity.  Persons with NMO may demonstrate improved 10 
function with rehabilitation efforts; though gains may be lost to relapse    Future 11 
immunomodulatory intervention may augment the benefits of rehabilitation. 12 
 13 
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 3 
Text 20 
Neuromyelitis optica (NMO, Devic Syndrome, Devic’s Syndrome) is a demyelinating 21 
disorder distinguished by the combination of optic neuritis (ON) and myelitis.  These 22 
symptoms can be mischaracterized as multiple sclerosis (MS).   NMO has a more acute 23 
and severe course.  Although NMO is closely associated with MS, it has specific 24 
diagnostic criteria, and unique pathological features compared to prototypic MS.1,2,3,4   25 
 26 
 History 27 
In 1870, Sir Thomas Clifford Allbutt first described an association between myelitis and 28 
optic nerve disease.5  The myelitis followed optic nerve changes by approximately 3 29 
months.  In 1879, Erb reported a 52 year old man who developed recurrent optic neuritis 30 
followed by subacute myelitis.6  In 1880, Sequin reported that the associations in the 31 
literature, including Erbs’s were accidental.7  In 1882, Dreschfeld performed a pathologic 32 
exam in a case of optic neuritis and myelitis, reporting inflammation in both the spinal 33 
cord and optic nerves.8  In 1888, Gower's textbook recognizes that they are of a common 34 
cause.9  In 1894, Devic and his student Gault reviewed 16 previous cases, as well as 35 
another case, for Gault’s doctoral thesis and concluded that optic neuritis and myelitis 36 
constituted a distinct clinical entity.10,11 In the early to mid-1900’s Beck and Stansbury 37 
reported more cases but were unable to conclude whether this was a distinct entity from 38 
acute disseminated encephalomyelitis or MS.12,13    39 
 40 
Classification 41 
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Even recent texts have classified NMO as a variant of MS.  In the Far East, NMO was 42 
characterized as the optico-spinal variant of MS.  MS is characterized by two or more 43 
occurrences of central nervous system symptoms and signs separated in time and space.  44 
The McDonald criteria represent the currents standards in diagnosis for MS.14  Since the 45 
late 1800’s there have been several sets of the diagnostic criteria that have attempted to 46 
clarify the controversy of NMO as a distinct entity.9,10,15,16 .  The distinction between MS 47 
and NMO is necessary, particularly for the relapsing form, because of the significant 48 
difference in morbidity and mortality.17 Furthermore drugs useful for MS may not be 49 
appropriate for NMO.  In 1999, Wingerchuck et al proposed diagnostic criteria with 85% 50 
sensitivity and 48 % specificity.18  In 2006, his group revised the criteria to define the 51 
syndrome, reporting an impressive 99% sensitivity and 90% specificity.  The diagnostic 52 
criteria characterize NMO by optic neuritis, myelitis, and at least two of three criteria: 53 
longitudinally extensive cord lesion, MRI nondiagnostic for MS, or NMO-IgG 54 
seropositivity.4  55 
 56 
Demographics 57 
Like MS, NMO predominantly affects women.  The median age of onset for NMO is in 58 
the late 30’s as compared to the late 20’s for MS.  MS most commonly affects people of 59 
Northern European/Caucasian ancestry.  NMO comprises a relatively greater proportion 60 
of a non-Caucasian background.  The occurrence of ON or severe myelitis in a non-61 
Caucasian ancestry should increase diagnostic suspicion for NMO.19   62 
 63 
Clinical Course 64 
 5 
Wingerchuk et al. characterized the clinical course as either monophasic or relapsing.18  65 
The time course of presentation is usually characteristic for each type.  Patients with a 66 
monophasic course usually present with rapidly sequential presentation of myelitis and 67 
ON within a median of 5 days, while the relapsing course has an extended interval 68 
between the presentation of the myelitis and ON with a median of 166 days and 69 
occasionally 2 years between initial events. 70 
 71 
The initial presentation of monophasic NMO is more severe but recovery is better.  72 
Functionally, the monophasic patients are able to maintain some degree of independence 73 
despite moderate visual and motor deficits.  The relapsing disease may present with less 74 
initial severity and better recovery, but recurrent episodes diminish recovery gains.20  The 75 
relapsing course has a poor prognosis with more than half developing severe visual loss 76 
and an inability to ambulate without modification within 5 years of the disease onset.  77 
Furthermore, the patients are at high risk for high cervical myelitis causing respiratory 78 
failure and death.21   79 
 80 
Therapy 81 
Acute medical therapeutic recommendations in the literature are beyond the scope of this 82 
report.    In a rehabilitation setting, a patient may be admitted on azathioprine in 83 
combination with prednisone22 or rituximab23 as a measure to prevent recurrence.  Just as 84 
the diagnostic criteria continue to be refined, the medical treatments for acute episodes as 85 
well as prophylactic therapy are a work in progress.  The mainstay of rehabilitative 86 
therapy is to prevent complications, treat symptoms, and optimize recovery of function in 87 
 6 
order to reduce disability, handicap and improve well-being.  We present three patients 88 
stricken with relapsing NMO who under went a comprehensive inpatient rehabilitation 89 
program and their functionality at discharge.   90 
 7 
Case Reports 91 
Case 1 92 
A 49 year-old woman initially presented with fatigue and chest discomfort.  Five months 93 
later, she developed left leg numbness, inability to urinate, bilateral ascending sensory 94 
deficits to the level of T6, and unsteadiness with gait.  She was diagnosed with MS, and 95 
experienced nine episodes of recurring thoracic myelitis over four years.  These flares 96 
were treated with the standard MS therapies and rehabilitation.  She was independent in 97 
activities of daily living (ADLs) with modified independent mobility using a rolling 98 
walker.  After further work-up, she was diagnosed with NMO.  Her 10th episode began 99 
with neck pain and rapidly progressed to obtundation, flaccid tetraparesis, a C2 sensory 100 
level and ventilator dependent respiratory failure. After receiving acute medical therapy, 101 
she started to improve. 102 
 103 
On admission to an inpatient rehabilitation facility, physical examination revealed 104 
monocular blindness on the left, cognitive impairment, anxiety, and marked global 105 
weakness in manual muscle testing with right-side 0-1/5 and left-sided 2-3/5.  Absence of 106 
sensation to light touch and pinprick was noted from the level of T4.  Spasticity was 107 
generalized at 1/4 Ashworth scale. She required a foley catheter and bowel program.  She 108 
exhibited maximum deficits in many areas of function.  She was dependent for transfers, 109 
feeding, grooming, dressing, bathing, toileting (Table 1).  Several barriers in her function 110 
were high levels of anxiety accompanied by poor endurance and impaired concentration.   111 
 112 
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Over a 1.5 month period of inpatient rehabilitation, her cognitive function and anxiety 113 
improved, and she was able to focus and make functional gains.  Her endurance improved 114 
and she was able to actively participate in her program.  Her manual muscle testing 115 
improved to grades 3+/5 in her right upper limb, 4/5 in her left upper limb, and 1-2/5 in 116 
her lower limbs.  Sensation was intact to the level of T4 dermatome with partial 117 
preservation to T10.  Spasticity was 1/4 in the upper limbs and 2/4 in the lower limbs.  118 
Cystometrogram (CMG) revealed an insensate dyssynergic hyperreflexic bladder that 119 
requires a constant foley catheter.  She was continent with a bowel program.  Functional 120 
gains were made in feeding, grooming, and upper extremity dressing.  Many areas such 121 
as lower extremity dressing, toileting, and transferring had minimal improvement (Table 122 
1).  She was discharged home with plans for outpatient rehabilitation.   123 
 124 
Case 2 125 
A 43 year-old woman was initially diagnosed with multiple sclerosis then shortly 126 
afterwards developed right eye blindness.  Functionally, she was independent in ADLs 127 
and required a cane for modified independent mobility. Two years later, she developed 128 
lower extremity weakness with an inability to urinate which was later complicated by 129 
urosepsis.  Neurologic work-up concluded that she had NMO. 130 
 131 
On admission to our inpatient rehabilitation facility, physical examination revealed a 132 
female patient blind in the right eye with impaired vision in left eye.  Her upper extremity 133 
strength was 4/5 and lower extremity 0/5.  Sensation was decreased to light touch and 134 
pinprick, without a clear sensory level.  She had flaccid paraplegia and bilateral ankle 135 
 9 
contractures.  She required a foley catheter and bowel program.  She exhibited deficits in 136 
many areas of function.  Specifically, she was dependent in lower extremity dressing, 137 
toileting, bathing, and toilet/tub transfers (Table 1). 138 
 139 
Her flaccid paraplegia persisted after one month of rehabilitation.  CMG revealed an 140 
areflexic neurogenic bladder with some preservation of bladder sensation, which she 141 
managed by intermittent catheterization.  She also required a bowel program.  Functional 142 
gains were made in lower extremity dressing, bathing, and toilet transfers.  Areas such as 143 
toileting and tub transfers had minimal improvement (Table 1).  She was discharged to a 144 
skilled nursing facility.   145 
 146 
Case 3 147 
A 41 year-old women initially developed transient bilateral blindness, with left eye vision 148 
return.  Two years later, she developed chest discomfort accompanied by loss of 149 
sensation and movement below the level of T3.  Extensive work-up revealed cervical and 150 
thoracic myelitis and she eventually was diagnosed with NMO.  Prior to the presentation 151 
of weakness, she was independent in ADLs and ambulation. 152 
   153 
On admission our inpatient rehabilitation facility, physical examination revealed a female 154 
patient blind in the right eye.  Her upper extremity strength was graded 4/5 and lower 155 
extremity 0/5.  Sensation was decreased to light touch and pinprick below the level of C6 156 
with dysesthesias in her right upper extremity.  She had flaccid paraplegia.  She required 157 
a foley catheter and bowel program.  She exhibited deficits in many areas of function.  158 
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Specifically, she was dependent in bathing, lower extremity dressing and toilet/tub 159 
transfers (Table 1). 160 
 161 
Her course of rehabilitation was complicated by urosepsis and pulmonary embolism.  162 
Eventually, she was able to complete 1 month of uninterrupted rehabilitation.  Her 163 
physical exam revealed persistent paraplegia with right upper extremity weakness and 164 
dysesthesia.  CMG revealed an areflexic neurogenic bladder without detrusor contraction 165 
or sensation.  She required a foley catheter and bowel program.  Functional gains were 166 
made in feeding, lower extremity dressing, and bathing.  Areas such as toileting and tub 167 
transfers had no improvement (Table 1).  She was discharged home.   168 
 169 
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Discussion 170 
NMO is a severe central nervous system demyelinating syndrome distinct from MS; 171 
characterized by optic neuritis, myelitis, and at least two of three criteria: longitudinally 172 
extensive cord lesion, MRI nondiagnostic for MS, or NMO-IgG seropositivity.  Literature 173 
search reveals that NMO is poorly described in the physiatric literature.  This is most 174 
likely due to the low incidence and prevalence as well as an evolving understanding of 175 
the clinicopathological features that set it apart from MS.  176 
 177 
There are a myriad of symptoms and signs of NMO, which must be addressed in a 178 
rehabilitation setting to maximize functional recovery.  Fatigue can be treated with a 179 
planned regiment of rest between therapies, focused energy efficient compensatory 180 
strategies, and psychostimulant medications.  Spasticity can be treated with frequent 181 
stretching of spastic muscles.  Incorporation of spasmolytic medications with close 182 
monitoring for enhancement of function versus hindering function may assist in overall 183 
functional improvement.  Other useful modalities are localized nonsystemic blocks and 184 
baclofen pumps.  Weakness may improve with progressive resistance exercises which 185 
may improve function.  Care must be taken not to overfatigue the muscles.  Neurogenic 186 
bladder must also be addressed to prevent long term complications of infection, 187 
hydronephrosis, stone formal, vesicouretal reflux, and renal failure.  CMG can establish 188 
the presence of sphincter dyssyngergia, detrusor hyperreflexia, or detrusor areflexia.  189 
Depending upon the severity of the bladder dysfunction, the patient’s mental status and 190 
upper limb dexterity, medications, indwelling catheterization or intermittent 191 
catheterization may be implemented in an acute rehabilitation setting.  Anxiety and 192 
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depression are common.  The utilization of a psychologist, group meetings and 193 
medications can help make the patient a more active participant in a program.  194 
Interventions for memory impairments include the use of a memory books (which must 195 
be appropriate for the patient’s visual deficits and possible loss of hand dexterity), a 196 
structured environment, and consideration of medications such as donezepil.    197 
 198 
Physiatrists need to focus on optimizing acute rehabilitation in order to treat symptoms, 199 
minimize complications and improve the quality of life.   This is even more pertinent 200 
with NMO versus MS because of the severe sequalae that occur after an acute episode.  201 
Rehabilitation planning must consider the progressive nature of the disease and risk of 202 
relapse.  Kraft says, “…We need to adapt rehabilitation strategies to a progressive 203 
neurologic disease with an uncertain course.24” Although he was referring to MS, this 204 
concept applies to NMO as well. 205 
 206 
Each of these three patients was not able to return to baseline ADL and ambulatory 207 
function after relapse.  However, they were able to improve in several domains of 208 
function from their initial assessment on admission to a rehabilitation facility.  Our first 209 
patient was significantly hindered by cognitive impairment, anxiety and fatigue, which 210 
improved during her stay. Consequently, she was able to improve her function and had 211 
less apprehension when she returned to the community.  Our second patient was admitted 212 
with a much stronger functional profile and was able to become much less dependent 213 
after her rehabilitation.  Our third patient provides an example of how medical 214 
complications, just as with MS, spinal cord injury, stroke, and traumatic brain injury, can 215 
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interrupt rehabilitation.  The patient and her rehabilitation team persevered so that her 216 
quality of life was improved.  In turn, the period between discharge and her next relapse, 217 
she will have improved function.   218 
 219 
All three patients benefited from acute rehabilitation.  Although they did not return to 220 
prior functional levels, they were able to improve. Functional gains can be expected, with 221 
attention to treating symptoms and preventing complications, through a comprehensive 222 
rehabilitation program. 223 
 224 
Conclusion 225 
Although rehabilitation strategies for MS are well reported in the literature, those for 226 
NMO are not. This may be due to a historical confounding of rehabilitation modalities for 227 
NMO with MS. The neurological literature now shows that there are unique clinical 228 
characteristics22, 23, 25 and pathological processes that distinguish MS from NMO. These 229 
differences may affect the neurological therapy and acute management of the disease. 230 
Thus, as newer treatments become available, it will be necessary to modify and optimize 231 
rehabilitation strategies to treat symptoms and prevent complications to maximize 232 
recovery of function.  Just as controlled clinical trials will need to be developed to 233 
identify the best acute care neurological treatments; controlled trials will need to be 234 
developed to assess recovery of function in the acute care and long term rehabilitation 235 
settings.  In order to do this we will need to determine the best set of outcomes measures 236 
for comparison of inpatient rehabilitation treatments.  As documented in our patient 237 
series, functional gains can be made by a comprehensive rehabilitation program.  238 
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